Ilhan Nevin, Ilhan Necip, Deveci Figen
Department of Biochemistry and Clinical Biochemistry, Firat University, Elazig, Turkey.
Clin Biochem. 2004 Sep;37(9):840-5. doi: 10.1016/j.clinbiochem.2004.03.012.
VEGF is one of the key factors in tumor angiogenesis that may be involved in tumor growth and metastasis. VEGF receptor, a naturally occurring soluble form of the VEGFR-1 (sVEGFR-1. flt-1), is produced by endothelial cells by differential splicing of the flt-1 gene, and is a negative counterpart of the VEGF signaling pathway.
We investigated the levels of VEGF and sVEGFR-1, a known intrinsic inhibitor of VEGF, in 42 patients with various types of lung cancers before beginning treatment and 18 healthy subjects.
Serum sVEGFR-1 levels (mean +/- SD; pg/ml) were 465.17 +/- 158.34 in patients and were significantly higher than those of the healthy subjects (156.39 +/- 89.17) (P < 0.0001). Serum VEGF levels of patients (449.48 +/- 175.54 pg/ml) were significantly higher in patients than in healthy subjects (77.06 +/- 47.26 pg/ml) (P < 0.0001).
We conclude that increased sVEGFR-1 and VEGF levels are important parameters in lung cancers.
血管内皮生长因子（VEGF）是肿瘤血管生成的关键因素之一，可能参与肿瘤的生长和转移。VEGF受体是血管内皮生长因子受体-1（VEGFR-1，flt-1）的一种天然存在的可溶性形式，由内皮细胞通过flt-1基因的可变剪接产生，是VEGF信号通路的负性对应物。
我们在42例各类肺癌患者治疗前及18名健康受试者中，研究了VEGF和sVEGFR-1（一种已知的VEGF内源性抑制剂）的水平。
患者血清sVEGFR-1水平（均值±标准差；pg/ml）为465.17±158.34，显著高于健康受试者（156.39±89.17）（P<0.0001）。患者血清VEGF水平（449.48±175.54 pg/ml）显著高于健康受试者（77.06±47.26 pg/ml）（P<0.0001）。
我们得出结论，sVEGFR-1和VEGF水平升高是肺癌的重要参数。
